Published on

Urology – Prostate Cancer: Locally Advanced Disease (Clinical T3–T4)

Definition, Pathophysiology, Risk Factors, Diagnostic Evaluation, Multimodal Treatment, and Prognosis

1. Definition and Clinical Overview

Locally advanced prostate cancer refers to prostate malignancy that extends beyond the prostate gland or invades adjacent anatomical structures.

The principal clinical stages are:

  • cT3: Tumour extends beyond the prostate capsule or involves the seminal vesicles.
  • cT4: Tumour is fixed or invades adjacent structures other than the seminal vesicles.

Locally advanced disease may be accompanied by regional lymph node involvement, but lymph node status must be recorded separately.

Main Clinical Categories

  • cT3N0M0.
  • cT4N0M0.
  • cT3–T4N1M0.

Clinical Importance

Compared with organ-confined prostate cancer, locally advanced disease is associated with:

  • Greater tumour burden.
  • Increased likelihood of lymph node involvement.
  • Greater risk of biochemical recurrence.
  • Increased probability of distant metastasis.
  • Higher prostate cancer-specific mortality.

Key Clinical Principle: Locally Advanced Prostate Cancer Frequently Requires Multimodal Treatment Because Surgery, Radiotherapy, Or Hormonal Therapy Alone May Be Insufficient For Durable Disease Control.


2. Clinical T3 Prostate Cancer

Definition

Cancer extending beyond the prostate gland.

Clinical findings may be identified through examination, while MRI provides additional information about the local extent.

T3 Subclassification

T3a – Extraprostatic Extension

Tumour extends through the prostatic capsule.

Extension may be unilateral or bilateral.

T3b – Seminal Vesicle Invasion

Tumour invades one or both seminal vesicles.

Clinical Importance

Seminal Vesicle Invasion Represents A More Advanced Local Tumour Pattern Than Extraprostatic Extension Alone.


3. Clinical T4 Prostate Cancer

Definition

Cancer that is fixed or invades adjacent structures beyond the seminal vesicles.

Important Structures

  • External urethral sphincter.
  • Rectum.
  • Levator muscles.
  • Pelvic wall.

Historical Source

The original chapter also describes bladder neck involvement as a T4 pathological feature.

Important Staging Qualification

Under contemporary pathological staging, microscopic bladder neck invasion is classified as pT3a, rather than automatically as pT4.

Stage assignment should distinguish microscopic bladder neck involvement from extensive macroscopic invasion or fixation.

Clinical Importance

T4 Disease Represents Extensive Local Invasion And Generally Requires Particularly Careful Multidisciplinary Treatment Planning.


4. Clinical Versus Pathological Stage

Clinical Stage

Based on pretreatment evaluation.

The EAU clinical T classification uses digital rectal examination findings, while MRI findings are reported separately for additional local staging information.

Pathological Stage

Determined by examination of surgically removed tissue.

Important Pathological Findings

  • Extraprostatic extension.
  • Seminal vesicle invasion.
  • Surgical margin status.
  • Lymph node metastases.

Clinical Importance

Clinical T3 Disease Does Not Always Correspond To Pathological T3 Disease Because Clinical Staging Can Both Overestimate And Underestimate Tumour Extent.


5. Epidemiology

Historical Incidence

The source describes a decline in locally advanced prostate cancer presentation during the PSA screening era.

1989–1990

Approximately 10–15% of prostate cancer presentations.

2001–2003

Approximately 1–5%.

Clinical Interpretation

Earlier detection contributed to a greater proportion of cancers being diagnosed while clinically localized.

Important Qualification

These percentages represent historical populations and should not be interpreted as current global incidence estimates.


6. Risk Factors

The probability of locally advanced disease increases with adverse tumour characteristics.

Principal Predictors

  • Higher PSA.
  • Higher Gleason score.
  • Higher ISUP Grade Group.
  • Greater tumour volume on biopsy.
  • More extensive positive biopsy involvement.

Clinical Importance

A High PSA Combined With High-Grade Histology And Extensive Biopsy Involvement Strongly Raises Concern For Extraprostatic Disease.


7. Age and Other Associated Factors

Increasing Age

The source reports a greater likelihood of high-risk prostate cancer presentation among men aged 75 years or older.

Historical Population Associations

The source also describes associations involving:

  • African American men.
  • Diabetes mellitus.

Important Qualification

These were historical observational associations. Disease severity is influenced by biological risk, healthcare access, screening, and other factors.

Such characteristics should not independently determine cancer stage or treatment.


8. Genetics

The historical chapter notes ongoing research into molecular markers that distinguish organ-confined from locally advanced prostate cancer.

Contemporary Genetic Considerations

Relevant genes include:

  • BRCA2.
  • BRCA1.
  • ATM.
  • CHEK2.
  • HOXB13.
  • Selected mismatch-repair genes.

Clinical Significance

Inherited or tumour-acquired molecular abnormalities may influence:

  • Cancer aggressiveness.
  • Hereditary risk assessment.
  • Treatment selection in advanced disease.

Important Principle

Genetic Testing Supplements Clinical Risk Assessment But Does Not Replace PSA, Grade Group, Imaging, Or Histopathological Staging.


9. Pathophysiology

Basic Mechanism

Locally advanced prostate cancer develops when malignant cells acquire the ability to penetrate normal anatomical barriers.

Important Biological Processes

  • Loss of normal cellular adhesion.
  • Extracellular matrix degradation.
  • Tissue invasion.
  • Altered growth signaling.
  • Angiogenesis.
  • Lymphovascular invasion.

Anatomical Progression

  1. Cancer develops within the prostate.
  2. Tumour grows beyond its original glandular structures.
  3. Extraprostatic extension develops.
  4. Seminal vesicles or adjacent structures may become involved.
  5. Regional or distant spread may subsequently occur.

Clinical Importance

Higher-Grade Prostate Adenocarcinoma Has A Greater Tendency Toward Extraprostatic Extension Than Low-Grade Cancer.


10. Histological Grade and Local Extension

Historical Comparison

Gleason 7–10

More commonly associated with extraprostatic disease than:

Gleason 6.

Modern Classification

  • Grade Group 1: Gleason 3 + 3.
  • Grade Group 2: Gleason 3 + 4.
  • Grade Group 3: Gleason 4 + 3.
  • Grade Group 4: Gleason 8.
  • Grade Group 5: Gleason 9–10.

Clinical Importance

Grade Groups 4–5 are particularly associated with aggressive disease and greater progression risk.


11. Associated Clinical Conditions

Locally invasive prostate cancer may cause symptoms through obstruction or direct invasion.

Important Manifestations

  • Hematuria.
  • Weak urinary stream.
  • Straining.
  • Urinary retention.
  • Irritative lower urinary tract symptoms.
  • Pelvic pain.
  • Changes in bowel habits.

Important Qualification

Some patients with locally advanced cancer remain relatively asymptomatic.


12. Prevention and Chemoprevention

The original chapter discusses several proposed preventive interventions.

Five-Alpha-Reductase Inhibitors

  • Finasteride.
  • Dutasteride.

Historical prevention studies demonstrated reduced prostate cancer detection rates.

However, these agents are not routinely recommended solely to prevent clinically significant prostate cancer.

Vitamin Supplements

The source specifically identifies no established benefit from:

  • Vitamin E.
  • Selenium.
  • Vitamin C.

Other Proposed Agents

  • Statins.
  • Green tea.
  • Lycopene.

Clinical Importance

There Is Insufficient Evidence To Recommend These Medications Or Supplements Specifically To Prevent Locally Advanced Prostate Cancer.


13. Diagnostic Evaluation

Main Objectives

  1. Confirm prostate adenocarcinoma.
  2. Determine tumour grade.
  3. Estimate local tumour extension.
  4. Assess seminal vesicle involvement.
  5. Evaluate regional lymph nodes.
  6. Exclude distant metastases.
  7. Assess suitability for curative treatment.


14. Clinical History

Family History

Ask about:

  • Prostate cancer in first-degree relatives.
  • Early-onset prostate cancer.
  • Relevant hereditary cancer syndromes.

Lower Urinary Tract Symptoms

Assess:

  • Weak urinary stream.
  • Hesitancy.
  • Urinary frequency.
  • Urgency.
  • Nocturia.
  • Retention.

Other Symptoms

  • Hematuria.
  • Pelvic pain.
  • Altered bowel habits.
  • Bone pain.
  • Weight loss.

Clinical Importance

New Bone Pain Or Systemic Symptoms Should Raise Concern For Metastatic Disease Rather Than Purely Locally Advanced Cancer.


15. Digital Rectal Examination

DRE.

Important Findings

  • Prostatic nodularity.
  • Induration.
  • Unilateral or bilateral abnormalities.
  • Loss of normal anatomical boundaries.
  • Prostatic fixation.
  • Extension into surrounding tissues.

Clinical Importance

A Fixed Prostate Or Palpable Invasion Of Adjacent Structures Raises Concern For Clinical T4 Disease.

Important Limitation

DRE alone may not accurately determine the full extent of the tumour.


16. Serum PSA

Clinical Role

PSA is a major component of prostate cancer risk assessment and staging.

Historical Positive Predictive Values

The source reports:

PSA 4–10 ng/mL

Approximately 12–32%.

PSA greater than 10 ng/mL

Approximately 60–80%.

Important Qualification

These are historical cancer-detection probabilities from particular clinical populations, not probabilities of locally advanced disease.

Clinical Importance

Higher PSA levels generally raise concern for greater tumour burden and more advanced disease, but PSA alone cannot establish tumour stage.


17. Factors Influencing PSA

PSA may be altered by:

  • Prostate volume.
  • Benign prostatic hyperplasia.
  • Prostatitis.
  • Urinary infection.
  • Recent urinary retention.
  • Relevant instrumentation.
  • Five-alpha-reductase inhibitors.

Historical Laboratory Variation

The source reports variability of approximately:

20–25%.

Important Qualification

Analytical and biological PSA variability differ across assays and circumstances.

Unexpected results should be interpreted using repeated measurements when appropriate.


18. PSA Density

Definition

Serum PSA divided by prostate volume.

Formula

PSA Density = PSA / Prostate Volume.

Historical Thresholds

Greater Than 0.15 ng/mL/cm³

Associated with increased suspicion for prostate cancer.

Greater Than 0.35 ng/mL/cm³

Associated with a reported 66% risk of extraprostatic extension in a historical cohort.

Important Qualification

These figures are historical and should not be used as stand-alone contemporary staging thresholds.


19. PSA Velocity

Definition

The rate of PSA change over time.

Historical Criterion

Increase greater than 0.75 ng/mL/year.

Historical Assessment Method

At least three PSA measurements over approximately 18 months.

Contemporary Qualification

PSA velocity is not recommended as the sole basis for diagnosing cancer or estimating local stage.

Clinical Importance

PSA Kinetics May Contribute To Clinical Risk Assessment But Must Be Interpreted Alongside Grade Group, MRI, And Other Findings.


20. Percentage Free PSA

Historical Finding

Free PSA below 10%.

Associated with a reported prostate cancer probability of approximately:

56%.

Important Qualification

The probability depends on the total PSA and population studied.

Free PSA is mainly relevant to selected diagnostic decisions rather than accurate local T staging.


21. PCA3 Urine Test

Definition

A urinary molecular biomarker based on prostate cancer antigen 3 expression.

Historical Method

Urine collection following DRE.

Historical Performance

  • Sensitivity: 48%.
  • Specificity: 79%.

Clinical Role

Previously investigated to help decide whether repeat prostate biopsy was appropriate.

Important Qualification

PCA3 is not a routine staging investigation for locally advanced prostate cancer.


22. Transrectal Ultrasound

TRUS.

Historical Role

  • Evaluate the prostate.
  • Guide systematic needle biopsy.
  • Assess suspicious local abnormalities.

Historical Accuracy for Extracapsular Extension

  • Sensitivity: 23–66%.
  • Specificity: 46–86%.
  • Positive predictive value: 50–62%.

Clinical Importance

Conventional TRUS Has Limited Reliability For Detecting Extraprostatic Extension.

It should not be relied on as the sole local staging investigation.


23. Multiparametric MRI

Contemporary Role

MRI is an important investigation for local tumour assessment.

Main Applications

  • Detect extraprostatic extension.
  • Evaluate seminal vesicle invasion.
  • Assess neurovascular bundle involvement.
  • Identify adjacent structure invasion.
  • Guide targeted biopsy.
  • Assist radiation or surgical planning.

Historical Source

The chapter describes MRI as useful for differentiating T2 from T3 disease.

Clinical Importance

MRI Provides Important Information About Local Tumour Extension And Is More Useful Than Conventional TRUS For Many Local Staging Questions.


24. MRI Limitations

MRI cannot reliably identify every instance of microscopic extraprostatic extension.

Potential Difficulties

  • Small-volume extension.
  • Postbiopsy hemorrhage.
  • Inflammatory abnormalities.
  • Limited lesion conspicuity.

Clinical Importance

A negative MRI does not guarantee organ-confined disease.


25. Computed Tomography

CT.

Historical Indications

The original source recommends considering CT staging with:

  • PSA greater than 20 ng/mL.
  • Gleason score 8 or higher.

Contemporary Clinical Role

CT remains useful when evaluating:

  • Pelvic and abdominal lymphadenopathy.
  • Advanced anatomical abnormalities.
  • Upper urinary tract dilatation.
  • Other structural complications.

Important Limitation

CT may miss small-volume nodal metastases.


26. Bone Scintigraphy

Historical Threshold

PSA at least 20 ng/mL.

Clinical Purpose

Evaluate possible skeletal metastases.

Important Qualification

Bone scan use should depend on the full clinical risk and available imaging.

The PSA threshold in the historical source is not a universal rule.


27. PSMA PET/CT

Contemporary Role

PSMA PET/CT is a preferred staging modality for high-risk localized and locally advanced prostate cancer when available.

Important Applications

  • Detect pelvic lymph node metastases.
  • Identify distant lymph node disease.
  • Identify bone metastases.
  • Detect other distant metastatic lesions.

Clinical Importance

PSMA PET/CT Provides More Accurate Metastatic Staging Than Conventional CT And Bone Scintigraphy In Many Patients With High-Risk Prostate Cancer.

Important Qualification

Very small nodal metastases may remain undetected.

More sensitive staging can change a patient's apparent stage, and treatment recommendations must consider the imaging method used in the supporting clinical trials.


28. Historical ProstaScint Imaging

The source describes possible use of ProstaScint in locally advanced prostate cancer.

Contemporary Qualification

ProstaScint has largely been superseded by modern PSMA PET imaging.

It is not a preferred routine staging modality.


29. Prostate Biopsy

Clinical Role

Histological confirmation is generally necessary before definitive treatment.

Historical Method

TRUS-guided prostate biopsy.

Contemporary Approach

  • MRI-directed sampling where appropriate.
  • Targeted and perilesional cores.
  • Systematic sampling when indicated.
  • Transperineal approach preferred in European practice.

Clinical Importance

The Biopsy Must Establish Histology And Grade Group To Support Accurate Treatment Selection.


30. Seminal Vesicle or Targeted Additional Biopsy

The historical source describes biopsy of the capsule or seminal vesicles to demonstrate T3 disease.

Clinical Importance

Targeted sampling may be useful in selected situations when histological confirmation of suspicious extension would change management.

Important Qualification

Routine seminal vesicle biopsy is not required for every suspected locally advanced prostate cancer.


31. Histopathological Findings

Main Parameters

  • Prostate adenocarcinoma.
  • Gleason score.
  • ISUP Grade Group.
  • Tumour volume.
  • Percentage of positive biopsy cores.
  • Perineural invasion.
  • Other adverse histological patterns.

Clinical Importance

High-Grade Histology And Extensive Biopsy Involvement Are Important Predictors Of Advanced Disease And Future Recurrence.


32. Differential Diagnosis

Elevated PSA

Possible causes include:

  • BPH.
  • Acute prostatitis.
  • Chronic prostatitis.
  • Urinary tract infection.
  • Prostatic or urethral instrumentation.

Suspicious Imaging Findings

May represent:

  • Prostate cancer.
  • Prostatitis.
  • Prostatic infarction.
  • Other benign or malignant abnormalities.

Important Principle

No Single PSA Measurement, Examination Finding, Or Imaging Investigation Can Perfectly Predict Pathological Prostate Cancer Stage.


33. General Treatment Principles

Locally advanced disease has a greater risk of recurrence than low-grade organ-confined prostate cancer.

Principal Management Considerations

  • Clinical T stage.
  • PSA.
  • Grade Group.
  • Nodal status.
  • Metastatic status.
  • Age.
  • Life expectancy.
  • Comorbidities.
  • Urinary function.
  • Treatment preferences.

Main Treatment Options

  1. Radiotherapy with long-term ADT.
  2. Intensified radiotherapy-based treatment in eligible patients.
  3. Radical prostatectomy with pelvic lymph node dissection in selected patients.
  4. Postoperative radiation and/or systemic treatment when indicated.
  5. ADT alone when appropriate local treatment is not feasible.


34. Multimodal Treatment

Definition

Treatment using more than one therapeutic approach.

Important Examples

  • Radiotherapy + ADT.
  • Radiotherapy + ADT + abiraterone.
  • Radical prostatectomy + pelvic lymph node dissection.
  • Radical prostatectomy followed by salvage or selected adjuvant radiotherapy.
  • Surgery followed by additional systemic treatment when indicated.

Clinical Importance

Combined Local And Systemic Treatment Is A Central Principle In Managing Fit Patients With Locally Advanced Prostate Cancer.


35. Androgen-Deprivation Therapy

ADT.

Mechanism

Reduces androgen stimulation of prostate cancer.

Main Methods

  • GnRH agonists.
  • GnRH antagonists.
  • Bilateral orchiectomy.


36. GnRH Agonists

Examples

  • Leuprolide.
  • Goserelin.
  • Triptorelin.

Mechanism

Continuous pituitary GnRH receptor stimulation eventually suppresses LH secretion and testicular testosterone production.

Important Adverse Effect

Initial testosterone flare.


37. GnRH Antagonists

Examples

  • Degarelix.
  • Relugolix.

Mechanism

Direct suppression of GnRH receptor signaling.

Main Advantage

Rapid testosterone reduction without initial androgen flare.


38. Surgical Orchiectomy

Definition

Bilateral surgical removal of testicular androgen-producing tissue.

Clinical Role

A permanent form of androgen deprivation.

Limitations

  • Irreversibility.
  • Sexual dysfunction.
  • Psychological effects.
  • Other consequences of long-term testosterone suppression.


39. ADT Monotherapy

Historical Source

The chapter describes ADT as an option for patients unwilling or unable to undergo surgery or radiation.

Contemporary Position

ADT alone is generally less effective than appropriate combined local and systemic treatment for fit patients with locally advanced nonmetastatic prostate cancer.

Current Selection Principle

ADT monotherapy may be considered when local treatment is not feasible, particularly in selected patients with aggressive or symptomatic disease.

Clinical Importance

ADT Monotherapy Should Not Automatically Replace Definitive Local Treatment In A Fit Patient With Potentially Curable Locally Advanced Prostate Cancer.


40. Antiandrogen Monotherapy

Historical Observation

The original source describes antiandrogen monotherapy as less effective but sometimes associated with better tolerability.

Contemporary Principle

First-generation antiandrogen monotherapy is generally not recommended as a preferred treatment strategy for locally advanced disease.


41. Radical Prostatectomy

RP.

Clinical Role

Potential curative treatment in selected patients with clinically node-negative locally advanced disease.

Important Considerations

  • Patient fitness.
  • Tumour resectability.
  • MRI findings.
  • Risk of positive margins.
  • Probability of lymph node involvement.
  • Expected urinary and sexual outcomes.

Clinical Importance

Radical Prostatectomy Can Be Considered For Selected cN0 Locally Advanced Prostate Cancers As Part Of A Planned Multimodal Strategy.


42. Clinical Overstaging

Historical Source

Clinical T3 overstaging was reported in approximately:

7–27% of Patients.

Clinical Importance

Some tumours classified as clinically T3 may prove less extensive on final pathology.

Important Principle

Clinical T3 Classification Alone Should Not Automatically Exclude Radical Prostatectomy In An Otherwise Suitable Patient.


43. Pelvic Lymph Node Dissection

Historical Recommendation

Radical prostatectomy with pelvic lymph node dissection.

Contemporary EAU Position

When lymph node dissection is performed:

Use an Extended Pelvic Lymph Node Dissection Template.

Clinical Purpose

  • Determine pathological nodal status.
  • Improve staging.
  • Guide postoperative management.

Important Qualification

The therapeutic benefit of lymph node dissection itself remains less certain than its staging value.


44. Neoadjuvant ADT Before Surgery

Historical Source

Neoadjuvant ADT did not demonstrate a clear:

  • Cancer-specific survival benefit.
  • Overall survival benefit.

Contemporary Clinical Principle

Routine neoadjuvant ADT before radical prostatectomy is not established as standard treatment outside appropriate specialized or research settings.


45. Adjuvant Radiotherapy After Prostatectomy

Definition

Radiotherapy delivered following surgery before established biochemical recurrence.

Historical Source

The chapter recommends postoperative radiation for:

  • T3 disease.
  • Positive surgical margins.
  • Gleason 8–10.

Historical Dose

55–70 Gy.

Historical Timing

Within approximately one year of surgery, following improvement or stabilization of postoperative urinary symptoms.


46. Contemporary Adjuvant Versus Early Salvage Radiation

Modern randomized trials have changed postoperative management.

Main Strategies

Adjuvant Radiotherapy

Treatment delivered despite undetectable postoperative PSA because of adverse pathology.

Early Salvage Radiotherapy

Treatment initiated when a postoperative PSA rise indicates likely residual or recurrent cancer.

Contemporary Clinical Importance

Early Salvage Radiotherapy Is Preferred Over Routine Adjuvant Radiation For Many Patients With Adverse Prostatectomy Pathology.

This approach avoids unnecessary radiation in patients who would otherwise remain recurrence-free.


47. Patients Who May Benefit From Adjuvant Radiation

Current EAU guidance supports offering adjuvant radiotherapy in selected patients with:

  • pN0 disease.
  • Pathological T3.
  • ISUP Grade Group 4–5.
  • With or without positive surgical margins.

Important Qualification

This is a selected high-risk group, not an automatic recommendation for every pT3 patient.

Clinical Importance

Very High-Risk Pathology May Justify Adjuvant Radiotherapy Despite The General Preference For Early Salvage Treatment In Many Patients.


48. Postoperative Node-Positive Disease

pN1.

Potential Management Options

  • Adjuvant ADT.
  • Adjuvant ADT with radiotherapy.
  • Observation in carefully selected patients with limited nodal disease and undetectable PSA.

Clinical Importance

Postoperative node-positive disease requires individualized risk assessment.


49. External-Beam Radiotherapy

EBRT.

Historical Source

The chapter recommends definitive doses of approximately:

75–80 Gy

to appropriate target regions.

Historical Alternative

Approximately 40–50 Gy of EBRT combined with brachytherapy.

Important Qualification

Dose, fractionation, and treatment fields depend on contemporary radiation planning and are not universal fixed prescriptions.


50. Modern Radiation Techniques

Intensity-Modulated Radiotherapy

IMRT.

Volumetric Modulated Arc Therapy

VMAT.

Image-Guided Radiotherapy

IGRT.

Main Benefits

  • More accurate target coverage.
  • Improved dose conformity.
  • Reduced unnecessary exposure to the rectum and bladder.
  • Ability to deliver effective tumour doses.

Clinical Importance

Modern IMRT/VMAT With Image Guidance Is A Standard Technical Approach For Definitive Radiotherapy In Locally Advanced Prostate Cancer.


51. Radiotherapy With Long-Term ADT

Historical Recommendation

Approximately:

2–3 Years of ADT.

Contemporary EAU Recommendation

For cN0 locally advanced prostate cancer:

Radiotherapy Combined With At Least Two Years of ADT.

Clinical Importance

Long-Term ADT Combined With Radiotherapy Improves Cancer Outcomes Compared With Radiation Alone In Appropriate Locally Advanced Disease.


52. Brachytherapy Boost

Definition

Additional localized radiation delivered using radioactive sources within the prostate.

Main Types

  • High-dose-rate brachytherapy.
  • Low-dose-rate brachytherapy.

Current Role

May be offered in selected patients with:

  • cN0 disease.
  • Good urinary function.
  • Appropriate prostate anatomy.
  • Suitability for combined treatment.

Clinical Importance

Brachytherapy boost can improve local dose delivery but may increase urinary toxicity.


53. Treatment Intensification With Abiraterone

Drug

Abiraterone acetate.

Mechanism

Inhibits CYP17-dependent androgen synthesis.

Clinical Role

Additional systemic hormonal treatment for selected higher-risk nonmetastatic prostate cancer.

Important Requirement

Administered with an appropriate corticosteroid regimen and monitoring.


54. Abiraterone in cN0M0 Disease

Current EAU guidance recommends adding:

Two Years of Abiraterone

to definitive radiotherapy and long-term ADT for cN0M0 patients with at least two of the following:

  1. Clinical T3–T4.
  2. Gleason score 8 or higher.
  3. PSA at least 40 ng/mL.

Clinical Importance

Not Every cT3–T4 Patient Automatically Qualifies For Abiraterone; The Specified Additional High-Risk Criteria Must Be Met.


55. Abiraterone in cN1M0 Disease

Contemporary Recommendation

For suitable patients with regional lymph node involvement but no distant metastases:

  • Prostate and pelvic radiotherapy.
  • Long-term ADT.
  • Two years of abiraterone.

Clinical Importance

Clinically Node-Positive Nonmetastatic Prostate Cancer Often Warrants Intensified Combined Local And Systemic Treatment.


56. STAMPEDE Evidence

Main Clinical Question

Does adding abiraterone to standard treatment improve outcomes in high-risk nonmetastatic prostate cancer?

Key Finding

The trial program demonstrated improved:

  • Metastasis-free survival.
  • Overall survival.

Reported Six-Year Metastasis-Free Survival

Abiraterone-based treatment: 82%.

Standard treatment: 69%.

Important Qualification

These were trial population estimates and do not represent the expected outcome of every individual patient.


57. Adverse Effects of Abiraterone

Important concerns include:

  • Hypertension.
  • Hypokalemia.
  • Fluid retention.
  • Abnormal liver function.
  • Other cardiovascular or metabolic complications.

Clinical Monitoring

  • Blood pressure.
  • Serum potassium.
  • Liver function.
  • Clinical fluid status.


58. Cryotherapy

Historical Source

The chapter describes cryoablation as less effective than radiotherapy in a historical comparison involving T2c–T3 disease.

Reported Biochemical Failure

  • Cryotherapy: 87%.
  • Radiotherapy: 53%.

Important Qualification

These results represent a particular historical trial and should not be generalized to all contemporary techniques.

Contemporary Position

Cryotherapy Is Not Recommended As Routine Primary Treatment For Locally Advanced Prostate Cancer.


59. High-Intensity Focused Ultrasound

HIFU.

Mechanism

Produces local thermal tissue destruction through focused ultrasound.

Historical Source

Describes HIFU as investigational.

Contemporary Position

HIFU does not have an established role as routine primary treatment for locally advanced prostate cancer.


60. Focal Therapy

Principle

Targeted ablation of a selected tumour region.

Main Limitation

Locally advanced disease may extend beyond the treated area or contain occult multifocal tumour.

Clinical Importance

Focal Ablation Is Not An Established Substitute For Definitive Multimodal Treatment Of T3–T4 Prostate Cancer.


61. Clinical Trials

Patients with locally advanced disease may benefit from consideration of clinical trials evaluating:

  • New treatment combinations.
  • Treatment intensification.
  • Molecular imaging-guided treatment.
  • Novel hormonal therapy.
  • Other emerging strategies.


62. Prognosis

General Principles

Prognosis depends on:

  • Clinical stage.
  • ISUP Grade Group.
  • PSA.
  • Tumour volume.
  • Nodal involvement.
  • Metastatic status.
  • Treatment received.
  • Overall health.

Clinical Importance

Untreated Locally Advanced Prostate Cancer Carries A Substantial Risk Of Progression And Disease-Specific Mortality.


63. Historical Outcomes Without Treatment

The source reports broad survival estimates.

Five-Year Overall Survival

10–92%.

Ten-Year Overall Survival

14–78%.

Important Qualification

These ranges reflect widely varying historical patient groups.

They are not reliable individualized survival predictions.


64. Historical Radical Prostatectomy Outcomes

Five-Year Overall Survival

64–96%.

Ten-Year Overall Survival

13–72%.

Five-Year Cancer-Specific Survival

85–92%.

Ten-Year Cancer-Specific Survival

79–82%.

Important Qualification

These are historical observational estimates affected by patient selection and treatment practices.


65. Historical Radiotherapy Outcomes

Radiotherapy Alone

Five-year overall survival:

60–70%.

Ten-year overall survival:

Below 50%.

Radiotherapy With ADT

Five-year overall survival:

72–87%.

Clinical Importance

These historical findings support the principle that combined radiation and hormonal treatment improves outcomes in suitable patients.


66. Prognostic Importance of PSA Doubling Time

Historical Adverse Threshold

Less Than 10 Months.

Associated Findings

The source identifies increased biochemical recurrence risk in patients with:

  • Gleason score 8–10.
  • Short PSA doubling time.

Clinical Importance

Rapid PSA Doubling After Treatment Raises Concern For Aggressive Recurrent Disease And Increased Risk Of Metastatic Progression.


67. Complications of Untreated Locally Advanced Disease

Hematuria

May develop from local tumour invasion or associated urinary tract pathology.

Bladder Outlet Obstruction

Tumour growth may impair urinary outflow.

Urinary Retention

May require catheter drainage.

Ureterovesical Junction Obstruction

Locally advanced tumour may obstruct one or both distal ureters.

Clinical Consequences

  • Hydroureteronephrosis.
  • Renal impairment.
  • Recurrent urinary infection.
  • Possible acute kidney injury.


68. Management of Urinary Obstruction

Bladder Outlet Obstruction

Possible measures include:

  • Urethral catheterization.
  • Suprapubic catheterization when indicated.
  • Selected palliative transurethral resection.

Upper Urinary Tract Obstruction

Possible measures include:

  • Ureteral stent.
  • Percutaneous nephrostomy.

Clinical Importance

Obstruction-Related Renal Impairment May Require Urgent Drainage Independently Of The Definitive Prostate Cancer Treatment Plan.


69. Palliative Transurethral Resection

Channel TURP.

Clinical Role

May relieve severe bladder outlet obstruction in selected patients with advanced disease.

Important Qualification

This is intended for symptom relief rather than definitive oncological treatment.


70. Complications of Surgery

Potential complications include:

  • Bleeding.
  • Infection.
  • Urinary incontinence.
  • Erectile dysfunction.
  • Anastomotic stricture.
  • Lymphocele following pelvic lymph node dissection.
  • Other operative complications.

Important Consideration

More extensive local tumour involvement may increase surgical complexity.


71. Complications of Radiation Therapy

Urinary Complications

  • Dysuria.
  • Frequency.
  • Urgency.
  • Hematuria.
  • Radiation cystitis.
  • Urethral stricture.
  • Urinary incontinence.

Gastrointestinal Complications

  • Radiation proctitis.
  • Rectal bleeding.
  • Diarrhea.
  • Bowel urgency.
  • Rare severe rectal injury.

Sexual Complications

  • Erectile dysfunction.
  • Reduced sexual function.


72. Complications of ADT

Important adverse effects include:

  • Hot flushes.
  • Fatigue.
  • Loss of libido.
  • Erectile dysfunction.
  • Reduced muscle mass.
  • Increased fat mass.
  • Osteoporosis.
  • Metabolic disturbances.
  • Cardiovascular risk considerations.

Clinical Importance

Long-Term Hormonal Treatment Requires Bone, Metabolic, Cardiovascular, And Quality-of-Life Monitoring.


73. Follow-Up

Historical Source Schedule

PSA approximately:

Every Three Months Initially.

Intervals may gradually be extended toward annual follow-up in suitable stable patients.

Important Qualification

Monitoring frequency should reflect:

  • Treatment received.
  • PSA response.
  • Recurrence risk.
  • Ongoing ADT.
  • Clinical symptoms.


74. PSA Monitoring After Radical Prostatectomy

Expected Result

PSA should generally become undetectable or extremely low.

Persistent PSA

May suggest residual local or systemic disease.

Rising PSA

May indicate biochemical recurrence.

Clinical Importance

An Unexpected Postoperative PSA Trend Requires Evaluation According To Pathological Risk And Available Salvage Treatment Options.


75. PSA Monitoring After Radiotherapy

PSA usually decreases gradually.

Important Features

  • PSA nadir.
  • Time to nadir.
  • Subsequent PSA changes.

Standard Biochemical Recurrence Definition

PSA Nadir + 2 ng/mL.

Clinical Importance

PSA interpretation differs after prostatectomy and radiotherapy.


76. Evaluation of Suspected Recurrence

The historical source recommends additional imaging when PSA fails to reach an expected nadir or rises consecutively.

Historical Investigations

  • Bone scintigraphy.
  • CT.
  • ProstaScint.

Contemporary Investigations

  • PSMA PET/CT.
  • Pelvic MRI.
  • Other imaging according to clinical findings.

Clinical Importance

Imaging Should Be Selected When Its Findings Are Expected To Influence Salvage Or Systemic Treatment Decisions.


77. Management of Recurrence

Potential approaches include:

  • Salvage radiotherapy.
  • ADT.
  • Other systemic treatment.
  • Selected regional or metastasis-directed treatment.
  • Clinical trial participation.

Important Qualification

The treatment depends on whether recurrence is:

  • Local.
  • Regional.
  • Metastatic.


78. Clinical and Surgical Pearls

Definition and Staging

  • cT3 indicates extraprostatic extension or seminal vesicle invasion.
  • cT4 indicates fixation or invasion of adjacent structures.
  • Clinical and pathological T stages may differ.
  • Nodal and metastatic status must be assessed separately.

Risk Factors

  • High PSA.
  • High Gleason score.
  • High Grade Group.
  • Greater biopsy tumour volume.
  • Advanced local tumour findings.

Diagnostic Evaluation

  • DRE is important for clinical T staging.
  • MRI assesses local extension.
  • PSMA PET/CT improves metastatic staging.
  • Biopsy establishes histology and Grade Group.
  • No single investigation perfectly predicts pathological tumour extent.

Treatment

  • Radiotherapy With Long-Term ADT Is A Major Standard Treatment For cN0 Locally Advanced Disease.
  • Radical prostatectomy may be offered to selected cN0 patients.
  • Extended pelvic lymph node dissection is recommended when dissection is performed.
  • Two years of abiraterone is recommended for eligible very-high-risk or cN1M0 patients.
  • Routine primary cryotherapy and HIFU are not recommended.

Postoperative Treatment

  • Adjuvant radiotherapy is not mandatory for every pT3 patient.
  • Early salvage radiotherapy is appropriate for many patients with PSA recurrence.
  • Selected high-grade pT3 patients may benefit from adjuvant treatment.


79. Essential Examination Principles

1. Know the T3 Subclassification

T3a indicates extraprostatic extension, and T3b indicates seminal vesicle invasion.

2. Know the T4 Definition

Tumour fixation or invasion of adjacent structures beyond the seminal vesicles.

3. Understand the Importance of MRI

It helps determine local disease extent but cannot exclude every instance of microscopic extension.

4. Use PSMA PET/CT for Staging When Available

It is particularly valuable in high-risk and locally advanced cancer.

5. Recognize the Need for Multimodal Treatment

Combined local and systemic treatment is frequently necessary.

6. Remember the Standard cN0 Treatment

Radiotherapy with long-term ADT.

7. Know the ADT Duration

At least two years for appropriate locally advanced disease treated with radiation.

8. Know the Abiraterone Eligibility Criteria

For cN0M0, at least two of cT3–T4, Gleason score 8 or higher, and PSA at least 40 ng/mL.

9. Recognize cN1M0 Treatment Intensification

Prostate and pelvic radiotherapy with long-term ADT and two years of abiraterone in eligible patients.

10. Remember Surgery Is Still Possible

Selected cN0 patients may undergo radical prostatectomy as part of a multimodal plan.

11. Perform Appropriate Nodal Dissection

An extended template is recommended when pelvic lymph node dissection is performed.

12. Distinguish Adjuvant From Early Salvage Radiation

Routine adjuvant radiation is not necessary for all adverse pathological findings.

13. Avoid Routine Primary Cryotherapy or HIFU

They are not established treatments for locally advanced disease.

14. Recognize Urinary Complications

Locally advanced cancer may produce bladder outlet and distal ureteral obstruction.

15. Continue Long-Term PSA Surveillance

Post-treatment PSA kinetics help detect recurrence and determine further treatment.


80. Historical Clinical Context and Important Qualifications

Historical Incidence

The original source describes declining clinical presentation of locally advanced disease during the early PSA era.

These percentages are not current incidence estimates.

Historical PSA Predictive Values

The reported PSA positive predictive values apply to specific clinical populations and should not be used as universal staging probabilities.

PSA Density and PSA Velocity

The source describes specific numerical thresholds for cancer detection or extraprostatic extension.

Contemporary assessment combines biomarkers, Grade Group, MRI, and other validated predictors.

MRI

The source describes MRI as an adjunct with selected staging accuracy estimates.

Contemporary multiparametric MRI has a major role in local staging and treatment planning.

PSMA PET/CT

Not included in the historical source.

It is now a preferred staging investigation for high-risk and locally advanced disease when available.

Surgery for cT3 Disease

The source emphasizes the possibility of clinical overstaging.

This remains relevant: carefully selected patients should not automatically be excluded from surgery.

Adjuvant Radiotherapy

The historical chapter recommends adjuvant treatment broadly for T3 disease and positive surgical margins.

Contemporary randomized evidence supports early salvage radiation for many patients, while selected very-high-risk pathological groups remain candidates for immediate treatment.

Abiraterone

The original chapter predates STAMPEDE evidence supporting two years of abiraterone in selected high-risk nonmetastatic patients.

ADT Monotherapy

The source presents ADT as an option for patients unsuitable for other treatments.

Current practice emphasizes that eligible patients achieve better outcomes with appropriately combined local and systemic therapy.

Cryotherapy and HIFU

The historical source describes these as experimental or less effective approaches.

Current EAU guidance does not recommend them as primary treatment for locally advanced prostate cancer.

Historical Survival Estimates

The survival percentages should not be interpreted as modern individualized prognosis.

They reflect heterogeneous cohorts with substantial differences in tumour risk, selection, and treatment.


81. Historical Diagnostic Codes

ICD-9

185

Malignant neoplasm of prostate.

198.1

Secondary malignant neoplasm of other urinary organs.

198.82

Secondary malignant neoplasm of genital organs.

ICD-10 Codes Listed in the Source

C61

Malignant neoplasm of prostate.

C79.11

Secondary malignant neoplasm of bladder.

C79.82

Secondary malignant neoplasm of genital organs.

Important Coding Qualification

These codes are preserved from the historical source.

Direct contiguous invasion of neighboring structures by primary prostate cancer is not necessarily equivalent to a separate secondary metastatic malignancy at that site. Current coding must reflect the documented disease and applicable coding rules.


Final Urological Revision Summary

Locally advanced prostate cancer consists of clinically T3 or T4 prostate malignancy, characterized by extension beyond the prostate or invasion of neighboring structures.

Main Staging Features

T3a

Extraprostatic extension.

T3b

Seminal vesicle invasion.

T4

Fixation or invasion of adjacent structures beyond the seminal vesicles.

Major Risk Factors

  • High PSA.
  • High Grade Group.
  • Extensive biopsy involvement.
  • Greater tumour volume.
  • Adverse local examination findings.

Main Diagnostic Priorities

  1. Clinical examination and DRE.
  2. PSA assessment.
  3. Prostate MRI.
  4. Prostate biopsy.
  5. ISUP grading.
  6. PSMA PET/CT when available.
  7. Evaluation of regional lymph nodes.
  8. Exclusion of distant metastatic disease.
  9. Assessment of urinary function and fitness for treatment.

Contemporary Treatment Approach

cT3–T4 N0 M0

  • Definitive radiotherapy with long-term ADT.
  • Radical prostatectomy with appropriate nodal assessment in selected patients.
  • Selected brachytherapy boost.
  • Additional abiraterone when specified high-risk criteria are met.

cN1 M0

  • Prostate and pelvic radiotherapy.
  • Long-term ADT.
  • Two years of abiraterone in eligible patients.

After Radical Prostatectomy

  • Close PSA monitoring.
  • Early salvage radiotherapy when indicated.
  • Selected adjuvant radiotherapy for particularly high-risk pathology.
  • Additional systemic treatment according to nodal status and recurrence risk.

Patients Unable to Receive Definitive Local Treatment

  • Individualized hormonal or palliative management.

Main Complications

  • Bladder outlet obstruction.
  • Urinary retention.
  • Hematuria.
  • Distal ureteral obstruction.
  • Hydronephrosis.
  • Renal impairment.
  • Urinary incontinence.
  • Erectile dysfunction.
  • Radiation cystitis.
  • Radiation proctitis.
  • ADT-related metabolic and skeletal complications.

Main Prognostic Factors

  • PSA.
  • Clinical stage.
  • ISUP Grade Group.
  • Seminal vesicle invasion.
  • Nodal involvement.
  • PSA response and doubling time.
  • Overall patient health.
  • Treatment intensity and effectiveness.

Follow-Up Priorities

  • Serial PSA.
  • Testosterone assessment during ADT when appropriate.
  • Urinary symptom evaluation.
  • Renal function when obstruction is present.
  • Monitoring of treatment toxicities.
  • Imaging when recurrence or progression is suspected.
  • Long-term multidisciplinary surveillance.

The Central Urological Objective Is To Accurately Stage T3–T4 Prostate Cancer, Identify Regional And Distant Spread, Select Appropriate Multimodal Therapy, Optimize Cancer Control, Prevent Urinary Tract Complications, And Preserve Quality Of Life Through Careful Long-Term Follow-Up.

Image description
0 Comments